CDXS Stock Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Codexis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.90 |
| 52 Week High | US$4.91 |
| 52 Week Low | US$1.45 |
| Beta | 2.03 |
| 1 Month Change | -15.94% |
| 3 Month Change | 8.61% |
| 1 Year Change | -26.77% |
| 3 Year Change | -88.26% |
| 5 Year Change | -85.17% |
| Change since IPO | -78.13% |
Recent News & Updates
Recent updates
Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20
What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Codexis gets new executive chief
Jul 18Are Investors Undervaluing Codexis, Inc. (NASDAQ:CDXS) By 35%?
Jul 06Why Codexis, Inc. (NASDAQ:CDXS) Could Be Worth Watching
May 10Codexis: A Company Rooting Itself In A Blossoming Market
Apr 18We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Apr 09Does This Valuation Of Codexis, Inc. (NASDAQ:CDXS) Imply Investors Are Overpaying?
Mar 14Shareholder Returns
| CDXS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.1% | 4.5% | 1.2% |
| 1Y | -26.8% | 5.2% | 24.7% |
Return vs Industry: CDXS underperformed the US Life Sciences industry which returned 5.2% over the past year.
Return vs Market: CDXS underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| CDXS volatility | |
|---|---|
| CDXS Average Weekly Movement | 15.6% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CDXS's share price has been volatile over the past 3 months.
Volatility Over Time: CDXS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 174 | Stephen Dilly | www.codexis.com |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
Codexis, Inc. Fundamentals Summary
| CDXS fundamental statistics | |
|---|---|
| Market cap | US$203.88m |
| Earnings (TTM) | -US$76.24m |
| Revenue (TTM) | US$70.14m |
2.9x
P/S Ratio-2.7x
P/E RatioIs CDXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CDXS income statement (TTM) | |
|---|---|
| Revenue | US$70.14m |
| Cost of Revenue | US$71.69m |
| Gross Profit | -US$1.55m |
| Other Expenses | US$74.69m |
| Earnings | -US$76.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -1.08 |
| Gross Margin | -2.21% |
| Net Profit Margin | -108.69% |
| Debt/Equity Ratio | 0% |
How did CDXS perform over the long term?
See historical performance and comparison